Definitive Healthcare Corp AI Stock Analysis
Want to see DH full AI Analyst Report?
Definitive Healthcare Corp (DH) AI Stock Analysis
Definitive Healthcare Corp
(NASDAQ:DH)
The score is held back primarily by weak financial performance (large net losses, very negative ROE, and declining revenue) despite strong gross margins and positive cash flow. Technicals are a relative positive with the stock trading above major moving averages and a positive MACD, while the earnings call points to continued top-line pressure and weaker visibility even as profitability guidance improved. Valuation is difficult to support with a negative P/E and no dividend yield.
Definitive Healthcare Corp (DH) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $143.60M
- Dividend Yield
- ―
- Average Volume (3M)
- 673.86K
- Price to Earnings (P/E)
- -0.9
- Beta (1Y)
- 1.56
- Revenue Growth
- -6.18%
- EPS Growth
- 10.48%
- Country
- US
- Employees
- 682
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
Definitive Healthcare Corp Business Overview & Revenue Model
Company Description
Definitive Healthcare Corp. (DH), operating through its various subsidiaries, offers specialized commercial intelligence solutions for the U.S. healthcare industry. The company's services furnish essential data on healthcare providers and their activ...
Definitive Healthcare Corp Earnings Call Summary
The call conveyed a balanced message: clear near‑term top‑line pressures (Q2 revenue down 9% YoY, RPO and deferred revenue down double digits, professional services softness, and continued life sciences drag) alongside strong profitability, disciplined cost management, robust free cash flow (~$50M TTM), operational progress (integrations, win‑backs, digital activation growth), and product/AI momentum (Turbo pilot and AI embedding). Management tightened full‑year revenue guidance while raising profit/margin guidance and emphasized that improvements in net dollar retention and customer win‑backs underpin confidence in a return to growth over time.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Definitive Healthcare said Q2 results informed a tightened outlook: Q2 revenue was $55.2M (‑9% YoY) with adjusted EBITDA $14.6M (26% margin), adjusted net income $7.5M ($0.05 non‑GAAP EPS), adjusted gross profit $44.2M (80% margin, down 12% YoY but +100bps ex‑one‑time credit), unlevered free cash flow $11.6M in Q2 and $50M TTM, deferred revenue $89M (‑12% YoY), total RPO down 18% YoY and current RPO $150M (‑12% YoY), and a TTM adjusted EBITDA→unlevered FCF conversion of 75% (down ~5pts). For Q3 they guide revenue $54–55M (‑8% to ‑10% YoY) with subscription revenue flat sequential, professional services expected to show double‑digit growth but below prior expectations, adjusted operating income $10.5–11.5M, adjusted EBITDA $13.5–14.5M (25–27% margin), adjusted net income $5.5–6.5M and EPS ~$0.04–0.05 on ~145M shares. Full‑year 2026 guidance is revenue $220–222M (‑8% to ‑9% YoY), adjusted operating income $45.5–47.5M, adjusted EBITDA $57–59M (26–27% margin), adjusted net income $27–29M and EPS $0.18–0.20 on ~145M shares; management tightened top‑line visibility, lowered professional services expectations, but raised the EBITDA midpoint by $1M and expanded margin guidance ~100bps.
Definitive Healthcare Corp Financial Statement Overview
Summary
High gross margins (TTM ~69.5%) and consistently positive operating/free cash flow support fundamentals, and leverage has improved sharply (debt-to-equity ~0.03). However, DH remains deeply unprofitable (TTM net margin ~-69%), ROE is very negative (~-78%), free cash flow is trending down, and TTM/2025 revenue is declining—keeping the financial profile below average overall.
Income Statement
28NegativeBalance Sheet
62PositiveCash Flow
55Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 227.31M | 241.52M | 252.20M | 251.41M | 222.65M | 166.15M |
| Gross Profit | 158.02M | 183.28M | 197.47M | 203.93M | 180.03M | 125.47M |
| EBITDA | -166.20M | -141.86M | -567.24M | -241.23M | 26.23M | 23.08M |
| Net Income | -157.25M | -138.93M | -413.12M | -202.39M | -7.22M | -51.91M |
Balance Sheet | ||||||
| Total Assets | 488.65M | 735.49M | 1.09B | 1.83B | 2.12B | 2.12B |
| Cash, Cash Equivalents and Short-Term Investments | 190.30M | 180.89M | 290.16M | 308.07M | 331.87M | 387.50M |
| Total Debt | 164.28M | 172.67M | 253.11M | 267.93M | 275.85M | 270.68M |
| Total Liabilities | 300.19M | 356.50M | 482.19M | 626.73M | 640.68M | 617.78M |
| Stockholders Equity | 145.33M | 281.11M | 444.38M | 861.36M | 948.92M | 871.31M |
Cash Flow | ||||||
| Free Cash Flow | 24.19M | 37.06M | 45.85M | 38.21M | 27.25M | 18.48M |
| Operating Cash Flow | 37.16M | 53.78M | 58.20M | 41.19M | 35.58M | 25.21M |
| Investing Cash Flow | 52.65M | 153.88M | -26.41M | -31.78M | -248.90M | -46.73M |
| Financing Cash Flow | -20.25M | -150.79M | -56.75M | -25.58M | -26.70M | 384.37M |
Definitive Healthcare Corp Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DH, the sentiment is Positive. The current price of 1.34 is above the 20-day moving average (MA) of 1.18, above the 50-day MA of 1.06, and above the 200-day MA of 1.00, indicating a bullish trend. The MACD of 0.07 indicates Negative momentum. The RSI at 67.50 is Neutral, neither overbought nor oversold. The STOCH value of 67.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DH.
Definitive Healthcare Corp Risk Analysis
Definitive Healthcare Corp disclosed 73 risk factors in its most recent earnings report. Definitive Healthcare Corp reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksDefinitive Healthcare Corp Peers Comparison
Overall Rating
DOCS80Outperform
WAY76Outperform
PHR69Neutral
DH56Neutral
HCAT54Neutral
EVH51Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 80Outperform | $5.54B | 40.89 | 14.81% | ― | 6.48% | -43.66% | |
| 76Outperform | $5.30B | 39.34 | 3.41% | ― | 21.43% | 9.80% | |
| 69Neutral | $760.99M | 71.20 | 3.01% | ― | 12.93% | ― | |
| 56Neutral | $194.65M | -0.89 | -87.69% | ― | -6.18% | 10.48% | |
| 54Neutral | $98.24M | -0.46 | -128.24% | ― | -13.88% | -78.38% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 51Neutral | $444.50M | -0.88 | -129.54% | ― | 14.06% | -189.46% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DH | Definitive Healthcare Corp. Class A | 1.34 | -1.26 | -48.46% | |
| EVH | Evolent Health Inc. | 3.93 | 0.24 | 6.50% | |
| PHR | Phreesia | 12.26 | -6.79 | -35.64% | |
| HCAT | Health Catalyst | 1.29 | -0.74 | -36.45% | |
| DOCS | Doximity, Inc. | 30.67 | -15.75 | -33.93% | |
| WAY | Waystar Holding Corp. | 27.54 | -7.25 | -20.84% |
Definitive Healthcare Corp Corporate Events
Definitive Healthcare Holders Waive Tax Agreement Termination Rights
PositiveDefinitive Healthcare disclosed that holders of its tax receivable agreement, including affiliates of Advent International, Spectrum Equity, 22C Capital and founder Jason Krantz, have irrevocably waived their right to receive an early termination pay...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
